Edition:
United States

TESARO Inc (TSRO.OQ)

TSRO.OQ on NASDAQ Stock Exchange Global Select Market

83.54USD
3:59pm EST
Change (% chg)

$-2.36 (-2.75%)
Prev Close
$85.90
Open
$88.83
Day's High
$88.83
Day's Low
$83.35
Volume
380,630
Avg. Vol
303,192
52-wk High
$192.94
52-wk Low
$83.35

Latest Key Developments (Source: Significant Developments)

Tesaro announces European Commission approval of Zejula for women with recurrent ovarian cancer
7:00am EST 

Nov 20 (Reuters) - Tesaro Inc :Tesaro announces European Commission approval of Zejula for women with recurrent ovarian cancer.Tesaro Inc - ‍approval supported by "robust" data from a randomized phase 3 trial​.Tesaro Inc - ‍Tesaro plans to launch Zejula in Germany and UK this December, with launches in additional European countries to follow beginning in 2018​.  Full Article

Tesaro reports Q3 loss per share $0.47
Tuesday, 7 Nov 2017 04:05pm EST 

Nov 7 (Reuters) - Tesaro Inc ::Tesaro announces third-quarter 2017 operating results.Q3 loss per share $0.47.Q3 revenue $142.8 million versus I/B/E/S view $132.8 million.Q3 earnings per share view $-0.93 -- Thomson Reuters I/B/E/S.Tesaro Inc - ‍positive CHMP opinion issued for zejula in e.u. & commercial launch anticipated to begin by year-end​.  Full Article

Opko Health licensee Tesaro announces FDA approval of Varubi IV for delayed nausea, vomiting associated with chemotherapy
Thursday, 26 Oct 2017 10:19am EDT 

Oct 26 (Reuters) - Opko Health Inc ::Opko Health licensee Tesaro announces FDA approval of Varubi IV for delayed nausea and vomiting associated with chemotherapy.‍Tesaro is expected to launch Varubi IV in November 2017​.  Full Article

EU Medicines Agency publishes recommendations for Sept 2017
Friday, 15 Sep 2017 07:55am EDT 

Sept 15 (Reuters) - EU MEDICINES AGENCY::EU MEDICINES AGENCY RECOMMENDS APPROVAL OF TESARO INC'S <<>> NIRAPARIB DRUG FOR TREATMENT OF RECURRENT OVARIAN CANCER.EU MEDICINES AGENCY RECOMMENDS APPROVAL OF JANSSEN-CILAG INTERNATIONAL N.V.'S GUSELKUMAB DRUG FOR TREATMENT OF PLAQUE PSORIASIS.  Full Article

Tesaro Inc Q2 loss per share $2.82
Tuesday, 8 Aug 2017 04:05pm EDT 

Aug 8 (Reuters) - Tesaro Inc :Tesaro announces second-quarter 2017 operating results.Q2 loss per share $2.82.Q2 earnings per share view $-2.49 -- Thomson Reuters I/B/E/S.Qtrly total revenues $35.8 million versus $29.5 million.  Full Article

Tesaro, Takeda licensing agreement to develop, commercialize cancer therapy
Thursday, 27 Jul 2017 07:00am EDT 

July 27 (Reuters) - Takeda A/S [RIC:RIC:NYCMD.UL]:Tesaro and Takeda enter exclusive licensing agreement to develop and commercialize novel cancer therapy Niraparib in Japan.Tesaro will receive $100 million upfront payment and is eligible to receive additional milestone payments of up to $240 million.Says Takeda gains exclusive commercial rights for all potential future Niraparib indications in Japan.Tesaro says additional terms of this agreement were not disclosed.  Full Article

Tesaro sale process seen unlikely to result in a deal - CNBC
Thursday, 13 Jul 2017 09:43am EDT 

July 13 (Reuters) - :Tesaro Inc <<>> sale process seen unlikely to result in a deal - CNBC, citing sources.  Full Article

Tesaro says Janssen updated clinicaltrials.gov website to reflect janssen had placed temporary enrollment hold in the galahad ‍​
Monday, 12 Jun 2017 06:47am EDT 

June 12 (Reuters) - Johnson & Johnson :Tesaro says on June 9, Janssen updated clinicaltrials.gov website to reflect Janssen had placed temporary enrollment hold in the galahad trial ‍​- SEC filing ‍​.Tesaro says galahad trial is not on clinical hold, temporary enrollment hold is not due to any safety concerns.Tesaro says Janssen anticipates re-opening enrollment for galahad trial soon.  Full Article

ClinicalTrials.gov says Janssen's study of niraparib suspends recruitment
Friday, 9 Jun 2017 10:54am EDT 

June 9 (Reuters) - ClinicalTrials.gov::Janssen Research's study of niraparib in men with metastatic castration-resistant prostate cancer, DNA-repair anomalies suspended recruitment.Current participants in Janssen Research's study of niraparib remain active and on study treatment.  Full Article

BRIEF-Tesaro Inc is exploring a sale, asked for initial bids - CNBC, citing DJ
Wednesday, 31 May 2017 04:08pm EDT 

Adds source text:Tesaro shares soar more than 10 percent after DJ reports co is exploring a sale, asked for initial bids - CNBC, citing DJ.  Full Article

BRIEF-Tesaro announces European Commission approval of Zejula for women with recurrent ovarian cancer

* Tesaro announces European Commission approval of Zejula for women with recurrent ovarian cancer